Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

Alamar-NULISAseq

More Like This

PR Newswire associated0

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

PR Newswire associated0

Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer's Disease Research

PR Newswire associated0

Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

Fujirebio Expands Its Alzheimer’s Disease Test Menu With the Much Awaited and Fully Automated Lumipulse® G pTau 217 Plasma Assay for Research Use Only (RUO)

ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development

PR Newswire associated0

Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson's Research Through Development of Next Generation Biomarker Assays

PR Newswire associated0

Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids